Table 1.
Clinical characteristics of MS patients and controls
| Patient no. | Age* (years) | Sex* | Duration of MS (years) | Clinical subtype | Current DMT | EDSS | Control no. | Age (years) | Sex |
|---|---|---|---|---|---|---|---|---|---|
| 1 |
23 |
m |
4 |
RRMS |
(FTY/Plac) |
2.0 |
1 |
26 |
m |
| 2 |
23 |
m |
7 |
RRMS |
FING |
2.0 |
2 |
27 |
m |
| 3 |
32 |
m |
9 |
RRMS |
IF |
1,0 |
3 |
27 |
m |
| 4 |
32 |
m |
6 |
RRMS |
GA |
0.0 |
4 |
33 |
m |
| 5 |
34 |
m |
4 |
RRMS |
NAT |
3.5 |
5 |
35 |
m |
| 6 |
48 |
m |
3 |
RRMS |
IF |
2.0 |
6 |
45 |
m |
| 7 |
23 |
f |
6 |
RRMS |
NAT |
1.5 |
7 |
24 |
f |
| 8 |
25 |
f |
6 |
RRMS |
IF |
1.5 |
8 |
26 |
f |
| 9 |
25 |
f |
8 |
RRMS |
IF |
1.5 |
9 |
26 |
f |
| 10 |
28 |
f |
7 |
RRMS |
IF |
2.0 |
10 |
26 |
f |
| 11 |
29 |
f |
1 |
RRMS |
IF |
1.0 |
11 |
26 |
f |
| 12 |
31 |
f |
3 |
RRMS |
IF |
1.0 |
12 |
28 |
f |
| 13 |
33 |
f |
9 |
RRMS |
IF |
2.5 |
13 |
33 |
f |
| 14 |
36 |
f |
9 |
RRMS |
IF |
1.5 |
14 |
45 |
f |
| Mean |
30.1 |
|
5.9 |
|
Median |
1.5 |
Mean ± |
30.5 |
|
| ± SD | ± 6.8 | ± 2.5 | [range] | [0–3.5] | SD | ± 6.9 |
*Patients listed by gender and age.
m = male; f = female; EDSS = expanded disability status scale; RRMS = Relapsing-Remitting MS; SPMS = Secondary Progressive MS; DMT = disease modifying therapy with immunomodulators; FING = fingolimod; GA = glatiramer acetate; IF = interferon beta; MIT = mitoxantrone; NAT = natalizumab; (FTY/Plac) = fingolimod or placebo; patient participated in a randomized controlled treatment trial with undisclosed allocation.